Rituximab as a first step in tackling transformation
Lancet Haematol
.
2018 Aug;5(8):e326-e327.
doi: 10.1016/S2352-3026(18)30093-0.
Epub 2018 Jul 4.
Authors
Jessica Okosun
1
,
Robert Kridel
2
,
Jude Fitzgibbon
3
Affiliations
1
Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK. Electronic address: j.okosun@qmul.ac.uk.
2
Princess Margaret Cancer Centre-University Health Network, Toronto, ON, Canada.
3
Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.
PMID:
30078407
DOI:
10.1016/S2352-3026(18)30093-0
No abstract available
Publication types
Letter
Comment
MeSH terms
Antibodies, Monoclonal, Murine-Derived
Humans
Lymphoma, Follicular*
Rituximab*
Substances
Antibodies, Monoclonal, Murine-Derived
Rituximab
Grants and funding
15968/CRUK_/Cancer Research UK/United Kingdom